Navigation Links
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
Date:5/4/2009

mon cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2009, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an estimated 49,960 deaths (American Cancer Society, Cancer Facts and Figures 2009). The current standard of care is associated with significant side effects including neuropathy, which can limit its use and result in its discontinuation. Effective first-line, neuropathy sparing treatment for CRC is a major unmet medical need.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, Calif. , Oct. 20, 2014  PneumRx, ... of interventional pulmonology, today announced completion of enrollment in ... The RENEW Clinical Study is the FDA-approved IDE pivotal ... for severe emphysema. It was anticipated that ... in February 2013, would take until the end of ...
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Data Expected in the Third Quarter --, SAN ... ), a biotechnology company focused on the development of,compounds ... has completed the last patient visit in its carotid ... analyzed to determine,VIA-2291,s effect on inflammation, and the company ...
... TOKYO, July 10 Sosei Group Corporation,("Sosei"; TSE ... completion of a Japanese Phase III clinical trial ... acquired the,exclusive distribution rights to the product in ... was designed to evaluate the safety and prevented,pregnancy ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Sosei Announces Completion of Phase III Trial for NorLevo(R) 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... special MRI methods, researchers have identified a pattern of ... (MCI) that indicates a greater likelihood of progression to ... edition of Radiology . , "Previously, this ... probable Alzheimer,s disease," said the study,s lead author, Linda ...
... Inc., today filed a formal protest and requested a ... managed behavioral health care contract RFP 09-630-7903-0001, which was ... New Mexico believes a stay is in the best ... consumers who will be adversely affected by the potential ...
... Feb. 9 The following is a statement from ... Director, American Public Health Association:"At a time when more ... to the nation,s public health system as a way ... (APHA) is thoroughly disappointed with the Senate,s decision to ...
... Inc. (NYSE Alternext: IMM) today announced results for its ... months ended December 31, 2008, revenues were $563,000, as ... 31, 2007. The decrease was primarily attributable to ... agreement. Loss from operations for the three months ...
... to Host Phoenix Arizona Celebrity GalaCOSTA MESA, Calif., Feb. 9 ... Dodgers, will co-host a celebrity casino event to benefit families ... Oakland A,s and World Series MVP. Kemp also serves ... (TACA). Kemp and Stewart host the celebrity-packed evening Ante ...
... ARLINGTON, Va., Feb. 9 BioInformatics, LLC ( http://www.gene2drug.com ... serving the life science industry -- will be a ... ( www.consumergeneticsshow.com ) in Boston, MA at the Hynes ... will also be exhibiting at the show. The ...
Cached Medicine News:Health News:MRI shows brain atrophy pattern that predicts Alzheimer's 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 3Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 4Health News:APHA Urges Congress to Include Public Health Provision in Stimulus Bill 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 3Health News:Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism 2Health News:BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009 2
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... ™ Airway., ,The LMA Flexible™ ... allows it to be positioned away ... a good seal. This makes it ... surgery, or other procedures where the ...
... The Most Versatile LMA™ Airway., ,The ... airway. The double cuff design enables seal ... be achieved. The drain tube separates the ... with the flexible airway tube, enable longer ...
Medicine Products: